Amid the unrelenting quest for disease-modifying treatments, uniQure’s groundbreaking progress with the FDA on an accelerated approval pathway for AMT-130 gene therapy in Huntington’s disease has set the biotech industry abuzz. A shift in the composite Unified Huntington’s Disease Rating Scale (cUHDRS) as an intermediate clinical endpoint, combined with the use of natural history external […]